| Gene | Timepoints- on treatment | Additional tests | Follow-up post therapy | Notes |
| KMT2A rearrangements | Bone marrow MRD- post 2 and end of treatment | BM 3 monthly for 2 years | Ensure rare fusions are suitable for MRD and baseline (ELN DAVID 2025) |
Note: if molecular MRD not available due to rare gene fusion, recommend use of flow MRD on bone marrow samples. Follow up 3 monthly for 12 months